SLC9A1 and prostate carcinoma: The DU145 human prostate cancer cell line showed a marked expression of both NHE1 and V-ATPase proton pumps, comparable to that observed for the androgen-insensitive PC3 human prostate cancer cell line, hence representing a promising anti-cancer target for PPIs [53,54,55].